1:05
When is the use of MRD appropriate?
Rafael Fonseca
1:06
Response to MM therapy can vary based on a variety of factors
Shaji Kumar
3:12
Prognostic indices for follicular lymphoma: PRIMA-PI
Marek Trneny
3:17
Improving outcomes after transplant in AML
Charles Craddock
3:02
New technologies informing SOC in DLBCL
Christian Gisselbrecht
1:25
Bringing CAR T-cells to the second-line setting
Jeremy Abramson
1:54
FORTE update: carfilzomib-lenalidomide induction therapy for MM
Francesca Gay
2:15
Multiple myeloma subgroups for risk-adapted therapy
Vittorio Montefusco
2:19
Novel avenues for MM treatment: CAR T-cells, venetoclax, induction & MRD
Nikhil Munshi
2:31
How to treat high-risk mutated myeloma
Nikhil Munshi
4:28
Advances in the classification of agressive myeloma
Nikhil Munshi
2:28
Preventing early disease progression in follicular lymphoma
John Seymour
1:21
Promising results for KBd therapy in R/R MM
Francesca Gay
2:23
FORTE: effective treatment of newly diagnosed MM with KRd
Francesca Gay
3:25
MUK Nine b: OPTIMUM, paving the way to effectively treat newly diagnosed high-risk MM
Martin Kaiser
1:54
CASTOR trial update: daratumumab/bortezomib/dexamethasone is an important regimen for R/R MM
Katja Weisel
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals